On March 03, 2026 Wedbush maintained an Outperform rating on Larimar Therapeutics, Inc. (LRMR) and raised its price target to $12. The LRMR analyst rating update keeps Wedbush aligned with a growth view while the market reacted with a 1.85% move, or $0.10. This note is notable because Wedbush is a recognized life sciences desk and its view can influence trading in thinly covered biotechs. We summarize the rating action, the new price target, and what investors should weigh now.

LRMR analyst rating: Wedbush maintains Outperform and raises price target

On March 03, 2026 Wedbush kept an Outperform rating on Larimar Therapeutics, Inc. (LRMR) and set a new price target of $12. The firm described the change as a reflection of updated model inputs and program milestones. StreetInsider published the full note and details are available here.

What the LRMR analyst rating change means for investors

A maintained Outperform signals Wedbush expects LRMR to outperform peers over the next 12 months. Investors should view the rating as continued confidence rather than a fresh bullish pivot. The raised $12 price target tightens valuation expectations and sets a clear reference for upside.

LRMR analyst rating and stock performance

The market reaction was modest with a 1.85% increase, equal to $0.10, on the day of the note. With a market cap of $471,603,054, Larimar Therapeutics, Inc. remains a mid-cap biotech where single reports often move price. Analysts’ language and targets tend to drive trading volume in these names.

Historical context of LRMR analyst rating and coverage

Coverage for Larimar Therapeutics, Inc. has been limited compared with large-cap peers. Wedbush is one of the more visible firms covering LRMR, and its calls carry weight with specialized biotech desks. That scarcity of coverage means each update, like this March 2026 note, can shift the consensus and investor attention quickly.

LRMR price target implications and valuation context

A $12 price target frames expectations versus current trading levels and guides risk-reward. For investors this creates a concrete upside benchmark and a point to test assumptions on revenue, clinical readouts, or partnerships. The maintained Outperform plus higher target implies Wedbush expects improving fundamentals or milestone delivery.

How Meyka AI tracks LRMR analyst rating and next steps

We monitor the LRMR analyst rating in real time and flag changes for subscribers using AI-powered coverage tools. Our platform aggregates price targets, rating moves, and historical notes to show how a firm like Wedbush shifts the consensus. Investors should watch subsequent filings and clinical updates that could confirm or contradict the analyst view.

Final Thoughts

Wedbush’s March 03, 2026 note kept an Outperform on Larimar Therapeutics, Inc. (LRMR) and raised the price target to $12. The LRMR analyst rating signals continued confidence from a notable life-sciences desk and provides a measurable upside reference. The immediate market response was a 1.85% move, or $0.10, showing modest market confirmation. Given limited coverage, each analyst update matters more for LRMR than for larger names. Investors should weigh the new target against company milestones, cash runway, and upcoming data events.

Meyka AI rates LRMR with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guarantees and are for informational purposes only; we are not financial advisors. For full note details, see the Wedbush coverage on StreetInsider and our LRMR page for continuous updates Meyka LRMR page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.